

538,990

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
8 July 2004 (08.07.2004)

PCT

(10) International Publication Number  
**WO 2004/056367 A1**

(51) International Patent Classification<sup>7</sup>: **A61K 31/502**,  
A61P 35/00

[US/US]; 177 Commonwealth Ave., Boston, MA 02116  
(US).

(21) International Application Number:  
PCT/IB2003/006091

(74) Agents: **DOHMANN, George, R.** et al.; Novartis AG,  
Corporate Intellectual Property, CH-4002 Basel (CH).

(22) International Filing Date:  
16 December 2003 (16.12.2003)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,  
GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ,  
OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ,  
TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/435,049 20 December 2002 (20.12.2002) US

(84) Designated States (*regional*): Eurasian patent (AM, AZ,  
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,  
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU,  
IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for all designated States except US*): **DANA-  
FARBER CANCER INSTITUTE INC.** [US/US]; 44 Bin-  
ney Street, Boston, MA 02115 (US).

**Published:**

— with international search report

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **KAELIN, William**

*For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: TREATMENT OF VON HIPPEL LINDAU DISEASE

(57) Abstract: The present invention relates to a method of treating VHL comprising administering a therapeutically effective amount of a compound described in the specification to a warmblooded animal in need thereof.

WO 2004/056367 A1